ERBB2 and gastric carcinoma: HER2 positivity, combining expression and amplification, was significantly associated with worse survival: OS 32.3 months HER2 positive versus 93.9 months HER2 negative (HR 0.42; 95% CI 0.18 – 0.93 Log Rank p = 0.028); which was confirmed in the OS analysis specific to the gastric carcinoma (HR 0.37; IC 95% 0.14–0.93 Log Rank p = 0.029) (Figure 3).